|
Female, n (%)
|
52 (83.9%)
|
431 (72.1%)
|
102 (82.3%)
|
390 (79.4%)
|
|
Age at diagnosis, years, median (IQR)
|
44.0 (34.0–52.0)
|
43.5 (33.0–52.0)
|
45.0 (34.0–51.5)
|
47.0 (38.0–54.0)
|
|
Age at start of 1st line, years, median (IQR)
|
51.0 (42.0–58.0)
|
53.0 (41.0–60.0)
|
52.0 (44.5–61.0)
|
55.0 (48.0–63.0)
|
|
Disease duration, years, median (IQR)
|
5.6 (3.0–7.8)
|
6.0 (2.5–11.8)
|
5.0 (2.2–12.1)
|
6.2 (3.0–12.9)
|
|
RF positive, n (%)
|
47 (75.8%)
|
428 (71.6%)
|
92 (74.2%)
|
389 (79.6%)
|
|
ACPA positive, n/total (%)
|
44/61 (72.1%)
|
399/587 (68.0%)
|
91/120 (75.8%)
|
348/480 (72.5%)
|
|
Presence of erosions, n/total (%)
|
25/38 (65.8%)
|
210/295 (71.2%)
|
46/67 (68.7%)
|
22/290 (76.6%)
|
|
Currently smoking, n/total (%)
|
10/53 (18.9%)
|
102/504 (20.2%)
|
26/103 (25.2%)
|
93/413 (22.5%)
|
|
Number of previous csDMARDs, n (%)
|
|
0
|
0 (0.0%)
|
8/592 (1.4%)
|
2 (1.6%)
|
6/484 (1.2%)
|
|
1
|
13 (21.0%)
|
226/592 (38.2%)
|
27 (21.8%)
|
131/484 (27.1%)
|
|
2
|
18 (29.0%)
|
147/592 (24.8%)
|
30 (24.2%)
|
165/484 (34.1%)
|
|
3
|
17 (27.4%)
|
112/592 (18.9%)
|
35 (28.2%)
|
113/484 (23.3%)
|
|
4+
|
14 (22.6%)
|
99/592 (16.7%)
|
30 (24.2%)
|
69/484 (14.3%)
|
|
Glucocorticoids in previous history, n (%)
|
56 (90.3%)
|
519/597 (86.9%)
|
112 (90.3%)
|
442 (90.0%)
|
|
Concomitant csDMARDs, n (%)
|
54 (87.1%)
|
549 (91.8%)
|
107 (86.3%)
|
440 (89.6%)
|
|
Concomitant MTX, n (%)
|
44 (71.0%)
|
454 (75.9%)
|
77 (62.1%)
|
349 (71.1%)
|
|
Concomitant GCs, n (%)
|
49 (79.0%)
|
446 (74.6%)
|
96 (77.4%)
|
402 (81.9%)
|
|
DAS28-ESR (0–10), median (IQR)
|
6.4 (5.7–7.0)
|
5.9 (5.3–6.5)
|
6.2 (5.6–6.8)
|
6.3 (5.8–6.8)
|
|
TJC (28 joints), median (IQR)
|
14.0 (11.0–19.0)
|
12.0 (9.0–16.0)
|
14.5 (9.0–19.0)
|
13.0 (10.0–18.0)
|
|
SJC (28 joints), median (IQR)
|
10.0 (7.0–13.0)
|
9.0 (6.0–12.0)
|
9.5 (6.0–12.5)
|
10.0 (7.0–13.0)
|
|
ESR (mm/h), median (IQR)a
|
33.5 (16.0–53.0)
|
28.0 (16.0–40.0)
|
32.0 (18.0–50.0)
|
34.0 (23.0–50.0)
|
|
CRP (mg/l), median (IQR)b
|
22.0 (9.4–34.0)
|
12.0 (5.3–23.5)
|
15.0 (7.9–31.0)
|
16.8 (8.0–33.1)
|
|
SDAI (0–86), median (IQR)c
|
40.5 (32.7–47.8)
|
35.6 (29.5–42.4)
|
39.3 (33.0–48.2)
|
39.0 (32.6–45.9)
|
|
PTGA (0–100), median (IQR)
|
78.0 (69.0–84.0)
|
70.0 (59.0–80.0)
|
75.0 (62.5–81.5)
|
75.0 (60.0–85.0)
|
|
MDGA (0–100), median (IQR)d
|
74.0 (60.0–80.0)
|
65.0 (52.0–75.0)
|
70.0 (58.5–80.0)
|
70.0 (60.0–80.0)
|
|
HAQ-DI (0–3), median (IQR)
|
1.8 (1.3–2.0)
|
1.4 (1.0–1.8)
|
1.8 (1.4–2.0)
|
1.8 (1.4–2.0)
|
|
EQ-5D (− 0.59–1), median (IQR)
|
0.1 (0.0–0.6)
|
0.2 (0.1–0.7)
|
0.1 (0.0–0.5)
|
0.1 (0.0–0.5)
|
